Doctorate in Business Administration (DBA) from Paris School of Business

One of China's 30 Most Influential Investors, Honorary President of the Hong Kong Association of Pharmaceutical Innovation, Founding Member of the Investment Committee of the China Pharmaceutical Innovation and Research Development Association (PhIRDA), Member of the BayHelix Group, CKGSB MBA Alumni Mentor (Class of 2025),and Distinguished Lecturer at Duke Kunshan University.

With over a decade of experience in the investment industry, he has focused on the biopharmaceutical sector, contributing to the advancement of the pharmaceutical industry. He has led investments in Heyuan Biosciences, Chipscreen Biosciences, Ascentage Pharma, Frontier Biotechnologies, Genuine Biotech, Qyuns Therapeutics, and others.

Accolades include:

CHC · Top 50 Most Influential Investors of the Year

FOF Weekly · Top 20 Best Healthcare Investors of 2023

CHC · Top 50 Most Influential Investors of 2022

ChinaVenture · Top 100 Chinese Best Venture Capitalists of 2021

Best Investor in the Medical and Health Industry 2020

China Financial Person of the Year Top 5 2019

Bachelor of Arts in Economics, University of California, San Diego; Member of the Global Entrepreneurship Leaders Program, PBC School of Finance, Tsinghua University; 2026 Fortune China 40 Under 40; 2025 Fortune China 40 Under 40 Most Promising Business Elite; First Batch of Young Investors, China Healthcare Investment H50; 2024 F40 China Young Investors by Zero2IPO; Initiated and deeply participated in the investment and exit of star projects including Healthgen Biotechnology, Asieris Pharmaceuticals, and Harbour BioMed; Formerly worked at the Asset Management Department of Guosen Securities.

Specializes in Information Technology, AI, and Life Sciences

Investment Committee Member of 30+ funds

Oversaw investment decisions in 130+ projects, with total value exceeding RMB 10.8 billion

Successfully exited 20+ companies (including CXMT and NIO)

Participated in the establishment of 4 USD-denominated funds

Ph.D., Zhejiang University; Postdoctoral Fellow, Baylor College of Medicine; Adjunct Professor, Zhejiang University School of Medicine

Principal Investigator (PI) at an independent laboratory in the United States; Supervisor for doctoral students and postdoctoral fellows; Recipient of multiple research grants, including the R01 grant from the National Institutes of Health (NIH)

A decade of experience in the pharmaceutical industry; previously worked at Lexicon Pharmaceuticals (USA), Hisun Pharma, and others; contributed to the market approval or clinical trial advancement of multiple products

Former Partner at Yingke Capital; full-spectrum coverage of pharmaceuticals, medical devices, IVD, and CXO; invested in over 30 portfolio companies

Bachelor of Arts in Economics

University of Washington, U.S.A.

Ten years of experience in financial management and corporate operations.

Former Role:

Group Finance Department, Huawei Technologies Co., Ltd. — with deep expertise in financial coordination, internal control, and organizational management.

Current Role:

Member of the Management Decision Committee, with overall responsibility for corporate financial management, human resources & administration, and digital transformation initiatives. Committed to advancing the standardization of corporate governance systems and enhancing organizational effectiveness.

Bachelor's degree in Pharmacy from Shanghai Jiao Tong University and Master's degree in Finance from Durham University, UK, with a multidisciplinary background. Five years of investment experience, specializing in medical devices and new materials. Successfully exited 4 investments, including 2 IPO projects.